The MIT Enterprise Forum of Cambridge's Innovation Series
spotlights Vaccines & Global Health: New Technologies Create Global Opportunities
this coming Monday, November 9, 2009 6-9p in the MIT Stata Center's Kirsch Auditorium...
"From SARS to HIV, infectious disease remains a global public health concern for emerging and developed nations alike... Pharma has recently cut a number of deals with emerging biotechnology companies piloting new approaches to infectious disease therapy to both address a pressing market need and help fill their pipelines. New funding for projects from basic research to vaccine development, has afforded academia and industry additional incentives to renew the commitment to developing new approaches to treating disease."
Value priced, especially for students! Keynote address by Dr Andrin Oswald
, CEO, Novartis Vaccines and Diagnostics Division, and a panel discussion featuring:
- Dr David Anderson, Vice President Immunology and Co-founder, Variation Biotechnologies
- Mustapha Leavenworth Bakali, CEO, Genocea Biosciences
- Michelle Dees, Director Innovation Fund, Internation AIDS Vaccine Initiative (IAVI)
- Moderator ~ Dr Una Ryan, President and CEO, Waltham Technologies, former President and CEO AVANT Immunotherapeutics
Supporting Organizations include Mass Bio, the Licensing Executives Society, the Harvard Biotechnology Club, and the Massachusetts Life Sciences Center. Organized by the incomparable Pearl Freier
of Cambridge BioPartners
Post a Comment